TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)
12.20
+0.10 (0.83%)
Feb 11, 2026, 1:30 PM CST
TPEX:4157 Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 58.85 | 74.14 | 374.66 | 243.11 | 364.93 | 60.85 |
Short-Term Investments | 696.87 | 751.28 | 598.2 | 591.11 | 495.38 | 197.22 |
Trading Asset Securities | 106.18 | 194.4 | 65.14 | 64.39 | 64.09 | 72.7 |
Cash & Short-Term Investments | 861.9 | 1,020 | 1,038 | 898.6 | 924.4 | 330.78 |
Cash Growth | -18.70% | -1.75% | 15.51% | -2.79% | 179.46% | -48.12% |
Accounts Receivable | 3.75 | 7.33 | 8.98 | 18.41 | 278.28 | 7.31 |
Other Receivables | 8.95 | 9.07 | 24.88 | 5.3 | 2.61 | 28.64 |
Receivables | 12.7 | 16.4 | 33.87 | 23.71 | 280.89 | 35.95 |
Inventory | 53.47 | 42.71 | 34.15 | 15.35 | 17.88 | 14.65 |
Other Current Assets | 15.87 | 7.16 | 4.37 | 11.57 | 8.84 | 10.22 |
Total Current Assets | 943.94 | 1,086 | 1,110 | 949.24 | 1,232 | 391.6 |
Property, Plant & Equipment | 48.08 | 67.47 | 90.61 | 56.6 | 80.43 | 42.47 |
Long-Term Investments | 3.05 | 2.45 | 9.71 | 23.98 | 53.9 | 85.86 |
Other Intangible Assets | 0 | 12.05 | 12.99 | 0.23 | 0.16 | 0.29 |
Other Long-Term Assets | 18.31 | 6.22 | 6.16 | 16.96 | 26.31 | 36.24 |
Total Assets | 1,013 | 1,174 | 1,230 | 1,047 | 1,393 | 556.45 |
Short-Term Debt | 35 | - | - | 3 | - | - |
Current Portion of Leases | 16.59 | 16.33 | 15.98 | 18.34 | 17.99 | 17.12 |
Current Income Taxes Payable | - | 0.11 | - | 3.07 | 27.86 | - |
Current Unearned Revenue | 0.17 | 0.15 | 0.15 | 0.15 | 0.18 | 44.41 |
Other Current Liabilities | 35.76 | 29.5 | 31.76 | 26.76 | 43.85 | 33.37 |
Total Current Liabilities | 87.52 | 46.08 | 47.89 | 51.32 | 89.88 | 94.91 |
Long-Term Leases | 29.91 | 42.39 | 58.71 | 17.13 | 35.47 | - |
Long-Term Unearned Revenue | 0.09 | 0.18 | 0.33 | 0.48 | 0.62 | 0.79 |
Pension & Post-Retirement Benefits | 3.18 | 3.31 | 4.01 | 8.05 | 13.15 | 18.57 |
Total Liabilities | 120.7 | 91.96 | 110.94 | 76.98 | 139.11 | 114.26 |
Common Stock | 20.94 | 20.94 | 20.94 | 20.91 | 20.91 | 20.91 |
Additional Paid-In Capital | 457.84 | 466.3 | 444.61 | 450.26 | 455.25 | 675.14 |
Retained Earnings | 481.06 | 640.6 | 678.68 | 542.05 | 778.3 | -300.21 |
Comprehensive Income & Other | -16.68 | -45.51 | -25.34 | -43.2 | -0.77 | 46.34 |
Shareholders' Equity | 892.68 | 1,082 | 1,119 | 970.03 | 1,254 | 442.18 |
Total Liabilities & Equity | 1,013 | 1,174 | 1,230 | 1,047 | 1,393 | 556.45 |
Total Debt | 81.5 | 58.71 | 74.69 | 38.47 | 53.46 | 17.12 |
Net Cash (Debt) | 780.4 | 961.11 | 963.3 | 860.13 | 870.94 | 313.66 |
Net Cash Growth | -21.76% | -0.23% | 12.00% | -1.24% | 177.67% | -45.10% |
Net Cash Per Share | 1.09 | 1.34 | 1.34 | 1.20 | 1.21 | 0.44 |
Filing Date Shares Outstanding | 717.84 | 717.84 | 717.84 | 716.84 | 716.84 | 716.84 |
Total Common Shares Outstanding | 717.84 | 717.84 | 717.84 | 716.84 | 716.84 | 716.84 |
Working Capital | 856.42 | 1,040 | 1,062 | 897.92 | 1,142 | 296.69 |
Book Value Per Share | 1.24 | 1.51 | 1.56 | 1.35 | 1.75 | 0.62 |
Tangible Book Value | 892.68 | 1,070 | 1,106 | 969.8 | 1,254 | 441.89 |
Tangible Book Value Per Share | 1.24 | 1.49 | 1.54 | 1.35 | 1.75 | 0.62 |
Machinery | 89.28 | 144.93 | 144.38 | 143.76 | 140.92 | 148.2 |
Leasehold Improvements | 1.67 | 60.79 | 60.66 | 60.71 | 60.67 | 58.11 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.